Quick Answer: Melanotan II is a synthetic peptide designed to stimulate tanning and has been investigated for sexual dysfunction. It is not approved by the FDA or any regulatory body worldwide, carries serious risks including melanoma-linked nevi changes, cardiovascular effects, and contamination dangers from unregulated gray-market sources. This article is educational — not a buying guide. If you’re considering Melanotan II, read this first.
When people search for Melanotan II online, they usually find one of two things: vendor pages selling it as a “research chemical,” or sensational news stories. What they rarely find is a calm, honest breakdown of what the science actually says — and what the risks really are.
That’s what this article is. We’re not here to sell you anything. We’re covering Melanotan II because it’s widely searched, widely misunderstood, and widely misrepresented by those with a financial stake in your purchase.
What Is Melanotan II?
Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide in the body. Alpha-MSH is part of the melanocortin system — a signaling network that regulates skin pigmentation, appetite, sexual function, and inflammation.
Melanotan II was developed in the early 1980s at the University of Arizona by researcher Dr. Victor Hruby and colleagues, initially as a potential treatment for skin cancer protection. The idea was straightforward: if you could trigger the body’s natural tanning response without UV exposure, you might reduce sun-seeking behavior and, by extension, reduce UV-related skin cancer risk.
That goal was medically noble. The execution, however, opened a Pandora’s box of complications — a story that continues today through underground use worldwide.
Melanotan II is not the same as Melanotan I. This distinction matters enormously, and we’ll cover it in detail below.
How Does Melanotan II Work?
To understand MT-II, you need to understand the melanocortin receptor system — specifically melanocortin 1 receptor (MC1R), which sits on the surface of melanocytes (skin cells that produce pigment).
Here’s the normal process:
- UV radiation damages DNA in skin cells
- Skin cells release signals (including α-MSH) in response
- α-MSH binds to MC1R on melanocytes
- MC1R activation triggers melanogenesis — the production of melanin pigment
- Melanin darkens the skin, providing some protection against further UV damage
Melanotan II mimics α-MSH but is far more potent and longer-lasting. It binds aggressively to MC1R — and also to several other melanocortin receptors (MC3R, MC4R, MC5R) throughout the body. This broad receptor activity is exactly why MT-II produces effects beyond skin darkening.
MC4R activation, in particular, plays a major role in sexual arousal. MT-II’s binding to MC4R in the brain is what produces the sexual side effects that drive much of its underground popularity today.
Why Do People Use Melanotan II?
There are two primary reasons people seek out MT-II:
1. Sunless Tanning
MT-II produces a tan-like darkening of the skin without requiring significant UV exposure. For people who want a darker complexion, can’t tan easily due to fair skin or MC1R gene variants, or want to reduce their time in the sun, this effect is appealing.
The problem is that the darkening isn’t purely cosmetic — it involves real biological changes to melanocytes. This is not the same as a spray tan. The implications of that distinction are significant and worrying (more on that below).
2. Sexual Dysfunction Research
MT-II’s potent activation of MC4R receptors in the central nervous system produces pro-erectile and libido-enhancing effects in both men and women. Early clinical trials showed impressive results for men with psychogenic erectile dysfunction.
This pharmacological pathway was actually spun off into a legitimate drug candidate: bremelanotide (PT-141), which was eventually FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is a modified version of MT-II with a better safety profile — and even it carries a black-box warning for blood pressure increases.
The sexual side effects of MT-II are strong enough that many users today inject it primarily for that purpose, with tanning as a secondary effect. This drives continued underground demand despite the compound’s unapproved status.
Melanotan I vs. Melanotan II: A Critical Distinction
These two peptides are frequently confused, and the confusion matters because their regulatory and safety profiles are completely different.
Melanotan I (afamelanotide) is a selective MC1R agonist. It was developed into a pharmaceutical drug, rigorously tested, and ultimately FDA-approved in 2019 under the brand name Scenesse for the prevention of phototoxicity reactions in adults with erythropoietic protoporphyria (EPP) — a rare genetic disorder causing severe pain upon sun exposure. Scenesse is implanted subcutaneously by a healthcare provider in a controlled medical setting.
Melanotan II took a different path. It showed early promise in University of Arizona clinical trials, but development stalled for multiple reasons — including its non-selective receptor binding, concerning side effects, and the complexity of its safety profile. It never completed the clinical trial pipeline. It is approved nowhere in the world for any indication.
The key distinction:
| | Melanotan I (afamelanotide/Scenesse) | Melanotan II | |—|—|—| | Receptor selectivity | Selective MC1R | MC1R, MC3R, MC4R, MC5R | | FDA approval | Yes (EPP, 2019) | No | | Clinical use | Medical implant, doctor-administered | Not approved | | Sexual side effects | Minimal | Significant | | Regulatory status | Approved pharmaceutical | Unapproved, gray market |
When vendors sell “Melanotan” without specifying which version — or refer to “MT-2” — they are almost always selling Melanotan II, the unapproved version.
The Safety Concerns: What the Data Shows
This is the section that gets buried in vendor marketing. Here’s what the actual research and clinical observations have documented:
Nevi Changes and Melanoma Risk
This is the most serious concern. Multiple case reports and studies have documented that MT-II use is associated with darkening, enlargement, and increased number of nevi (moles). Because melanoma arises from melanocytes — the same cells MT-II directly stimulates — this is a significant red flag.
Dermatologists have raised concerns that the potent, prolonged MC1R stimulation caused by MT-II could promote the growth of pre-malignant or malignant melanocytes. Several case reports in the medical literature describe new melanoma diagnoses in patients who had been using MT-II.
This does not definitively prove MT-II causes melanoma. Causation vs. correlation is genuinely complex here. But the biologically plausible mechanism — combined with documented nevi changes — is enough for dermatologists and oncologists to urge extreme caution.
If you have a personal or family history of melanoma, or if you have many moles or atypical nevi, the risk calculus here is particularly concerning.
Cardiovascular Effects
MT-II causes transient increases in blood pressure and heart rate — an effect well-documented even in the clinical bremelanotide trials. Some users report flushing, palpitations, and hypertension following injection.
These effects stem from MT-II’s broad melanocortin receptor activation in the cardiovascular system. For otherwise healthy individuals, these effects may be short-lived. For anyone with hypertension, heart disease, or cardiovascular risk factors, they represent a meaningful danger.
Nausea and Gastrointestinal Effects
Nausea is one of the most commonly reported side effects of MT-II — sometimes severe enough to cause vomiting, particularly at higher doses. This effect is consistent with MC4R activation in the brain’s nausea centers. It’s a predictable pharmacological outcome, not just an idiosyncratic reaction.
Spontaneous Erections
MT-II’s central MC4R activity frequently produces unwanted spontaneous penile erections in men — an effect that is actually sometimes sought by users, but which can be embarrassing and physically uncomfortable, particularly at higher doses.
Facial Flushing and Fatigue
Flushing of the face and fatigue are commonly reported in the hours following injection. These are considered typical side effects even in clinical research settings.
Unregulated Manufacturing and Contamination Risk
Perhaps the most immediately dangerous aspect of gray-market MT-II is what you actually receive when you buy it. Because MT-II is not a regulated pharmaceutical:
- Purity is unverified. Independent testing of gray-market peptides routinely finds products that are mislabeled, under-dosed, over-dosed, or contaminated.
- Sterility is not guaranteed. Injectable peptides require pharmaceutical-grade sterile manufacturing. Homebrew or poorly equipped labs cannot guarantee this. Injecting a non-sterile product carries risks of local infection, abscess, septicemia, and systemic infection.
- You don’t know what you’re getting. The compound sold as “Melanotan II” may contain other peptides, fillers, or unknown substances.
This layer of danger is entirely separate from MT-II’s inherent pharmacological risks — it’s about the supply chain itself.
What the FDA and Regulators Say
The FDA has issued warnings about Melanotan products multiple times. In 2018, the FDA warned consumers not to use any “tanning injections” or nasal sprays sold as Melanotan — noting that these products have not been evaluated for safety or efficacy and may pose significant health risks.
The FDA’s position is unambiguous: Melanotan II is not an approved drug, not an approved dietary supplement, and should not be injected or otherwise used.
Beyond the US, MT-II has been explicitly banned or restricted in:
- Australia (Therapeutic Goods Administration banned it in 2010 as a Schedule 4 substance)
- United Kingdom (Medicines and Healthcare products Regulatory Agency has issued warnings and enforcement actions)
- Canada (Health Canada has warned against use)
- European Union (Not approved; banned in several member states)
In countries where it isn’t explicitly scheduled, it typically exists in a gray-market “research chemical” status — sold with disclaimers like “not for human use” to circumvent regulation. This legal fiction does not protect users.
What Dermatologists Say
Dermatologists’ concerns center on two issues: nevi surveillance and the false security of a “safe tan.”
On nevi: Dermatologists strongly recommend that anyone who has used MT-II undergo a full-body skin examination by a board-certified dermatologist, with particular attention to any moles that have changed. The ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution) apply with extra urgency for MT-II users, because the “Evolution” part may be pharmacologically accelerated.
On tanning biology: A tan produced by MT-II is not simply a cosmetic change — it’s a real biological alteration to melanocytes. Some dermatologists argue this may not carry the same DNA-protective function as a UV-induced tan, making MT-II users potentially more vulnerable to UV damage even as their skin appears darker.
On the “safer tanning” marketing: Any framing of MT-II as a “safe” or “safer” alternative to sun exposure is viewed by dermatologists as misleading. Trading known UV risks for unknown melanoma and cardiovascular risks is not a reasonable safety trade-off.
The Research History: University of Arizona Origins
It’s worth acknowledging that Melanotan II wasn’t invented by shady internet vendors. It came from legitimate academic research.
Dr. Victor Hruby’s lab at the University of Arizona pioneered synthetic melanocortin analogs in the 1980s. The goal was genuinely to explore whether tanning could be induced as a form of UV protection. Early human trials in the 1990s at the University of Arizona did show that MT-II produced tanning and, unexpectedly, pronounced effects on sexual arousal.
The University of Arizona licensed the technology to a company that eventually pursued bremelanotide (the more targeted MC4R agonist eventually approved as Vyleesi) rather than MT-II itself. MT-II’s development as a pharmaceutical was not abandoned due to ineffectiveness — it was abandoned because the risk-benefit profile, particularly around melanoma risk, did not support approval.
That history matters. MT-II is not a quack compound with no research basis. It has real pharmacology, real research history, and real effects. It also has real risks — which is precisely why it never cleared the regulatory bar that Scenesse and Vyleesi eventually crossed.
The Bottom Line
Melanotan II is a pharmacologically active compound with a legitimate research history, real effects on skin pigmentation and sexual function — and a genuine, unresolved safety profile that has kept it off pharmacy shelves worldwide despite decades of research.
The case against using it comes down to several converging factors:
- No regulatory approval anywhere in the world — not for any indication
- Biologically plausible and case-report-documented melanoma risk via melanocyte stimulation and nevi changes
- Cardiovascular effects including blood pressure spikes
- Contamination and purity risks inherent to gray-market supply chains
- No physician oversight during use — no monitoring of moles, blood pressure, or cardiovascular status
If you’re interested in skin health, melanin protection, or sexual wellness, there are approaches with actual evidence bases and regulatory approval. Melanotan II is not among them.
This article is here because people deserve honest information rather than vendor-funded enthusiasm. The research says: the risks are real, the regulatory bars haven’t been cleared, and the supply chain itself is dangerous. That’s the honest picture.
Related Articles
- Best Supplements for Glowing Skin
- Best Longevity Supplements in 2026
- Best Anti-Inflammatory Supplements 2026
- Clean Beauty Makeup Guide
- Supplement Stacking Guide 2026
Sources
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. [PMID 23121206]
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. [PMID 23121206]
- Midazolam versus midazolam-promethazine combination for oral sedation in third molar surgery: A randomized split-mouth trial. [PMID 42001488]
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. [PMID 23121206]
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. [PMID 23121206]
Leave a Reply